CG
KLDO

Cutler Group’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Cutler Group’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-400
Closed -$2K – 6685
2021
Q2 		$2K Hold
400
– – ﹤0.01% 5157
2021
Q1 		$3K Buy
+400
New +$4.36K ﹤0.01% 4825

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cutler Group's KLDO Position: Q3 2021 in Review

Cutler Group sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q3 2021, closing a stake of 400 shares — an estimated $2K sold.

Cutler Group first reported a position in KLDO in Q1 2021 and held it in 2 quarters. The position peaked at $3K in Q1 2021. 71 funds tracked by Wall St. Rank hold KLDO as of Q3 2021.

  • Cutler Group reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Cutler Group sold 400 Kaleido Biosciences, Inc. Common Stock shares in Q3 2021, an estimated $2K.
  • Cutler Group first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Cutler Group's Kaleido Biosciences, Inc. Common Stock position peaked at $3K in Q1 2021.
  • 71 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q3 2021.

Based on Cutler Group's 13F filing for Q3 2021, filed 26 Oct 2021.